Wall Street analyst estimates for BeOne Medicines AG (ONC): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult...
Consensus price target
$406.22 (+8 % vs price $377.63)
between $367.00 and $459.00 · 6 targets published in the last quarter
Closing price, Oct 28
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $6.8B | $6.7B – $6.8B | $7.29 | 12 |
| 2027E | $7.8B | $7.6B – $7.9B | $10.28 | 12 |
| 2028E | $8.9B | $7.8B – $10.0B | $13.75 | 13 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 14 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $1.90 | ||
| 2026-08-05 | $2.05 | $1.63 | +25.8% |
| 2026-05-06 | $1.96 | $0.73 | +168.5% |
| 2026-02-26 | $0.58 | $1.60 | -63.7% |
| 2025-11-06 | $1.09 | $0.72 | +51.4% |
| 2025-08-06 | $0.84 | $0.48 | +75.0% |
| 2025-05-07 | $1.22 | $-0.71 | +271.8% |
| 2025-02-27 | $-1.43 | $-0.88 | -62.5% |
Valuation Ratios
| P/E Ratio | 5.22 |
| Price / Book | 10.68 |
| EV / EBITDA | 32.02 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $238.4M | $198.2M | $428.2M | $308.9M | $1.18B | $1.42B | $2.46B | $3.81B | $5.34B |
| Cost of Revenue | $98.0M | $274.0M | $707.7M | $71.2M | $70.7M | $164.9M | $286.5M | $379.9M | $594.1M | $668.5M |
| Gross Profit | -$97.0M | -$35.6M | -$509.5M | $357.0M | $238.2M | $1.01B | $1.13B | $2.08B | $3.22B | $4.67B |
| Research & Development | $98.0M | $269.0M | $679.0M | $927.3M | $1.29B | $1.46B | $1.64B | $1.78B | $1.95B | $2.15B |
| Selling, General & Admin | $20.1M | $62.6M | $195.4M | $388.2M | $600.2M | $990.1M | $1.28B | $1.51B | $1.83B | $2.08B |
| Operating Expenses | $20.1M | $62.9M | $196.3M | $1.32B | $1.90B | $2.45B | $2.92B | $3.29B | $3.78B | $4.23B |
| Operating Income | -$117.1M | -$98.5M | -$705.8M | -$959.9M | -$1.66B | -$1.44B | -$1.79B | -$1.21B | -$568.2M | $447.1M |
| EBITDA | -$115.2M | -$93.7M | -$695.4M | -$941.3M | -$1.63B | -$1.39B | -$1.89B | -$738.2M | -$361.2M | $616.8M |
| Interest Expense | $383,000 | $4.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $58.2M |
| Pre-tax Income | -$119.2M | -$91.1M | -$689.8M | -$943.6M | -$1.62B | -$1.44B | -$1.96B | -$825.8M | -$533.0M | $416.9M |
| Income Tax | $54,000 | $2.2M | -$15.8M | $7.0M | $10.4M | $19.2M | $42.8M | $55.9M | $111.8M | $129.9M |
| Net Income | -$119.2M | -$93.1M | -$673.8M | -$948.6M | -$1.62B | -$1.46B | -$2.00B | -$881.7M | -$644.8M | $286.9M |
| EPS | $-3.90 | $-2.21 | $-12.09 | $-15.86 | $-19.11 | $-15.21 | $-19.37 | $-8.45 | $-6.12 | $33.80 |
| EPS (Diluted) | $-3.90 | $-2.21 | $-12.09 | $-15.86 | $-19.11 | $-15.21 | $-19.37 | $-8.45 | $-6.12 | $32.11 |
| Shares Outstanding (Diluted) | 31.0 M | 41.8 M | 55.4 M | 60.1 M | 83.5 M | 92.8 M | 103.1 M | 104.4 M | 105.3 M | 113.4 M |
Price
| Price | $377.63 (closing price, October 28, 2026) |
| Market Cap | $40.4B |
| Exchange | NASDAQ |
| Country | CH |
Related companies: VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ONC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks